Freiburg, Germany, April 08, 2026: CorTec GmbH, a pioneer in fully implantable brain-computer interfaces (BCI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s Brain Interchange™ system. The designation covers the use of direct cortical electrical stimulation to support motor recovery in people living with chronic stroke-related impairments.
Mehr erfahren Sie in der Presseinformation:
Pressemitteilung CorTec
